Seoul National University Hospital Team Conducts 6.5-Year Follow-Up on 925 Patients
Early Predictive Value of "Left Atrial Reservoir Strain" for End-Stage Progression Confirmed
"Early Identification of High-Risk Patients Expected"

A Korean research team has proposed a new echocardiographic marker that enables early prediction of end-stage progression risk in patients with hypertrophic cardiomyopathy.


On July 7, Seoul National University Hospital announced that the research team led by Professors Hyung-Gwan Kim and Soon-Gu Kwak from the Department of Cardiology found that 'left atrial reservoir strain (LARS)' in patients with hypertrophic cardiomyopathy is an independent marker for predicting progression to end-stage heart failure.


A schematic diagram showing the main results of the study predicting end-stage hypertrophic cardiomyopathy progression using 'Left Atrial Reservoir Strain (LARS).' Seoul National University Hospital

A schematic diagram showing the main results of the study predicting end-stage hypertrophic cardiomyopathy progression using 'Left Atrial Reservoir Strain (LARS).' Seoul National University Hospital

View original image

Hypertrophic cardiomyopathy is a genetic heart disease characterized by abnormal thickening of the heart muscle. While symptoms are often not apparent in the early stages, as the disease progresses, it can deteriorate into an end-stage phase (left ventricular ejection fraction below 50%) with reduced cardiac pump function, leading to a significantly increased risk of heart failure and sudden cardiac death. However, the conventional marker, left ventricular ejection fraction (LVEF), often remains within the normal range during the early stages of the disease, which limits its ability to predict risk at an early stage.


The research team conducted a median 6.5-year follow-up on 925 patients diagnosed with hypertrophic cardiomyopathy between 2007 and 2023 who underwent serial echocardiographic evaluations for at least one year. As a result, 3.8% of all patients (35 individuals) progressed to the end-stage, and the 10-year cumulative progression rate was 4.4%. Among those who reached the end-stage, 29% experienced fatal cardiovascular events within approximately two years, underscoring the importance of early risk prediction.


Upon analyzing left atrial reservoir strain alongside conventional markers, the team found that for every 1 percentage point decrease in this value, the risk of end-stage progression increased by approximately 10%. In particular, patients with a left atrial reservoir strain below 16.9% had a 3.6-fold higher risk of end-stage progression compared to those with a value of 16.9% or higher.


Even after adjusting for conventional risk factors such as age, heart failure symptoms, left ventricular ejection fraction, left atrial size, and apical ventricular aneurysm, left atrial reservoir strain remained an independent predictor of progression to the end-stage.


Additional analysis of 491 patients who underwent cardiac magnetic resonance (CMR) imaging showed that left atrial reservoir strain remained an independent predictor, even after accounting for late gadolinium enhancement (LGE), a marker of myocardial fibrosis. Moreover, adding this indicator to existing prediction models significantly improved their predictive power.



Professor Soon-Gu Kwak stated, "It is crucial to closely monitor the disease progression in hypertrophic cardiomyopathy, so it is important to continuously assess and manage the heart's condition through regular echocardiographic examinations." Professor Hyung-Gwan Kim added, "Left atrial reservoir strain can be measured through routine echocardiography without the need for expensive specialized tests, making it highly practical for clinical use. We expect it will help identify high-risk patients more accurately and enable timely intervention." The study findings were published in the latest issue of the European Heart Journal – Cardiovascular Imaging.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing